-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Events
Celgene CEO on New Multiple Myeloma Drug Approvals
Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >
Simpson Bowles Keynote to Address Debt, Taxes, Government Services and Politics
I was recently asked what the single biggest threat to the biotechnology industry is today. My answer was immediate – the biggest threat to biotech innovation is the unsustainable mismatch of spending and revenue in the U.S. federal budget. The enormous national debt and the huge annual budget deficits that feed it endanger America’s entire economic future – but the nation’s dire fiscal situation is particularly threatening to our industry. Part of the reason for Read More >
Jim's Corner
Leave a comment
Email This Post
Tags: 2013 BIO International Convention, BIO Events, BIO International Convention, budget deficit, debt ceiling, Events, FDA, federal budget, finance policy, Food and Drug Administration, Health Care, Medicaid, medicare, National Institutes of Health, NIH, simpson-bowles
Tags: 2013 BIO International Convention, BIO Events, BIO International Convention, budget deficit, debt ceiling, Events, FDA, federal budget, finance policy, Food and Drug Administration, Health Care, Medicaid, medicare, National Institutes of Health, NIH, simpson-bowles
2013 BIO International Convention Program Highlights
I’m thrilled to be attending the upcoming 2013 BIO International Convention that is coming to Chicago April 22-25. The educational sessions, networking, business forum, and exhibits are coming together to form the strongest Convention to date. Of course, I may be biased being a Chicago native but I can’t think of a better venue and backdrop for the rapidly evolving biotechnology industry. The City of Chicago is known for its architects and novel designs, a Read More >
Delivering on the Promise of Personalized Medicine
As sequencing moves out of the lab and into the clinic, a host of players must get involved to make our collective promises of personalized medicine a reality. CEOs, entrepreneurs, researchers, clinicians, regulators and payers need to work together to take on the next challenges in the implementation of personalized medicine. Some of those challenges include: Cost vs. Benefit: How do we define and benefit from transformational technologies? Form vs. Function: What about the less Read More >
BIO Housing Inventory Going Fast
With roughly 80,000 bioscience jobs in more than 3,500 businesses across all bioscience sectors, it is no wonder the 2013 BIO International Convention is returning to Chicago, April 22- 25, 2013. With a large presence in all biotech sectors – agricultural feedstock and chemicals, drugs and pharma, medical devices and equipment, research, testing and medical laboratories and bioscience-related distribution, attendees will have the opportunity to meet with and visit premier R&D facilities, from national laboratories Read More >
